(4-ethoxyphenyl)boronic acid

• ChemBase ID: 10038
• Molecular Formular: C8H11BO3
• Molecular Mass: 165.98214
• Monoisotopic Mass: 166.08012461
• SMILES: c1c(ccc(c1)OCC)B(O)O
• Canonical SMILES: CCOc1ccc(cc1)B(O)O
• InChI: InChI=1S/C8H11BO3/c1-2-12-8-5-3-7(4-6-8)9(10)11/h3-6,10-11H,2H2,1H3
• InChIKey: WRQNDLDUNQMTCL-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (4-ethoxyphenyl)boronic acid
• IUPAC Traditional name: 4-ethoxyphenylboronic acid
• Synonyms: 4-Ethoxyphenylboronic acid; 4-Ethoxybenzeneboronic acid; 4-Ethoxybenzeneboronic acid; 4-Ethoxyphenylboronic acid; 4-Ethoxyphenylboronic acid; 4-Ethoxybenzeneboronic acid; 对乙氧基苯硼酸; 4-乙氧基苯硼酸

Database IDs

• CAS Number: 22237-13-4
• EC Number: 000-000-0
• MDL Number: MFCD00674028
• Beilstein Number: 3530408
• PubChem SID: 24869077; 160973345
• PubChem CID: 2734351

CALCULATED PROPERTIES

• Acid pKa: 8.879388
• H Acceptors: 3
• H Donor: 2
• LogD (pH = 5.5): 1.7294197
• LogD (pH = 7.4): 1.7155087
• Log P: 1.7296
• Molar Refractivity: 41.8153 cm^3
• Polarizability: 17.89069 Å^3
• Polar Surface Area: 49.69 Å^2
• Rotatable Bonds: 3
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Melting Point: 121-128 °C(lit.); 165-168°C

Safety Information

• Storage Warning: IRRITANT
• European Hazard Symbols: Irritant (Xi)
• German water hazard class: 3
• Risk Statements: 36/37/38
• Safety Statements: 26-37
• TSCA Listed: false; 否
• GHS Pictograms: GHS07
• GHS Hazard statements: H315-H319-H335
• GHS Precautionary statements: P261-P305+P351+P338-P302+P352-P321-P405-P501A
• Personal Protective Equipment: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter

Product Information

• Purity: 97%; 98%
• Linear Formula: C2H5OC6H4B(OH)2

DETAILS

Sigma Aldrich - 455539

Other Notes
Contains varying amounts of anhydride
Packaging
1, 10 g in glass bottle
Application
Reactant involved in Suzuki cross coupling reactions1Reactant involved in the synthesis of biologically active molecules including:
• Novel modulators of survival motor neuron protein for treatment of spinal muscular atrophy2
• Amino-trimethoxyphenyl-aryl thiazoles for use as microtubule inhibitors and antitumor agents3
• Bicyclic hydroxyphenyl methanone derivatives for use as hydroxysteroid dehydrogenase inhibitors4
• Dual immunosuppressive and anti-inflammatory agents5
• Antiproliferatives via Suzuki cross-coupling / amination reactions6